Spyre Therapeutics launches $350 million stock offering
Spyre Therapeutics entered an underwriting agreement for a public offering of 4,117,648 shares at $85.00 per share, targeting expected gross proceeds of about $350 million, with a 30-day option to buy up to 617,647 additional shares on the same terms.